Effectiveness of billig's exercise in reducing dysmenorrhea among adolescent girls in selected rural high schools of Kanpur, Uttar Pradesh: a one-group pre-test post-test study
Student's Journal of Health Research Africa · 2026-09-30 · 7 (3) · 8
DOI: 10.51168/c1arhf74 ↗Abstract
Background Dysmenorrhea is a common menstrual problem among adolescent girls. It causes painful menstruation, affects physical, psychological and social well-being, and can interfere with daily activities, school attendance and academic performance. This study assessed the effectiveness of Billig's exercise in reducing dysmenorrhea among adolescent girls in selected rural high schools of Kanpur, Uttar Pradesh. Methods A quasi-experimental one-group pre-test post-test design was used. Sixty adolescent girls were selected by purposive sampling. Data were collected with a structured questionnaire on socio-demographic variables and menstrual history and a modified numeric pain intensity scale. All participants received Billig's exercise. Pre-test and post-test scores were compared with a paired t-test at a significance level of 0.05. Results Most girls were aged 15–16 years (32, 53.33%), Hindu (41, 68.33%) and vegetarian (32, 53.33%), and 51 (85%) were in the 11–13-year category for age at menarche. The mean pain score fell from 5.18 (SD 2.81) at pre-test to 2.91 (SD 2.58) at post-test, a mean reduction of 2.27 points (t = 9.35, df = 59, p < 0.05). Severe pain fell from 22 (36.67%) to 7 (11.67%) girls and moderate pain from 16 (26.67%) to 11 (18.33%), while 12 (20%) girls reported no pain at post-test, compared with none at pre-test. Conclusion Dysmenorrhea pain scores were significantly lower after Billig's exercise. The absence of a control group means that this change cannot be attributed to the exercise alone. Recommendation Billig's exercise, which is simple and needs no equipment, may be taught in school health programmes as a non-pharmacological option for menstrual pain. Controlled trials with longer follow-up are needed to confirm the effect.
EUVIMED